Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides

Tonix Pharmaceuticals · 2022-10
arc beats above · slides in the middle · loops below · scroll → 1 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

29
every slide · same image gating as the playbook
01
Slide 1
Includes company logo, ticker symbol, conference name, and document versioning.front_matter
03
establish_context
Open slide detailBeat · ProblemLoop · Golden Circle
04
summarize
Open slide detailBeat · ProblemLoop · Golden Circle
05
The slide provides a comprehensive overview of clinical and preclinical programs with detailed footnotes explaining specific drug statuses and licensing agreemeanalyze_data
Open slide detailBeat · ProblemLoop · Golden Circle
06
transition
Open slide detailLoop · Golden Circle
07
The slide uses a split-layout: left side describes the drug product, right side lists clinical trial status for Fibromyalgia, Long COVID, and PTSD.other
Open slide detailBeat · SolutionLoop · Golden Circle
08
Includes clinical trial status (RELIEF, RALLY, RESILIENT) and market demographics.summarize
Open slide detailBeat · SolutionLoop · Golden Circle
09
Clinical trial design slide for Tonix Pharmaceuticals.present_framework
Open slide detailBeat · SolutionLoop · Golden Circle
10
Slide 10 of a corporate presentation deck.establish_context
Open slide detailBeat · SolutionLoop · Golden Circle
11
The slide outlines a clinical trial protocol for TNX-102 SL in Long COVID patients.present_framework
Open slide detailBeat · SolutionLoop · Golden Circle
12
Includes disclaimer about non-approval and patent status.establish_context
Open slide detailBeat · SolutionLoop · Golden Circle
13
Slide 13 of a Tonix Pharmaceuticals presentation.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
14
Includes clinical trial status and mechanism of action highlights.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
15
Slide provides a high-level summary of a pharmaceutical asset's profile and development roadmap.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
16
transition
Open slide detailBeat · Market SizeLoop · Golden Circle
17
The slide uses a two-column layout to contrast the disease profile with the development program status.frame_situation
Open slide detailBeat · Market SizeLoop · Golden Circle
18
transition
Open slide detailBeat · Market SizeLoop · Golden Circle
19
Includes a comparison of three generations of CD40L antibodies and a structural diagram of the antibody.present_solution
Open slide detailLoop · Golden Circle
20
The slide outlines a drug development asset in the immunology portfolio.present_solution
Open slide detailLoop · Golden Circle
21
transition
Open slide detailLoop · Golden Circle
22
The slide uses a split-layout design with a left-hand column for platform differentiators and a right-hand column for specific product status and next steps.present_solution
Open slide detailLoop · Golden Circle
23
The slide uses a process-like diagram to show the evolution from historical vaccines (Vaccinia, Horsepox) to a modern programmable 'Antigen Coding' platform.present_solution
Open slide detailLoop · Golden Circle
24
The slide lists three distinct facilities: RDC (Frederick, MD), ADC (North Dartmouth, MA), and CMC (Hamilton, MT).other
Open slide detailLoop · Golden Circle
25
transition
Open slide detailLoop · Golden Circle
26
The slide uses checkmarks for completed items and empty squares for future items.plan_implementation
Open slide detailLoop · Golden Circle
27
The slide uses a grid-like layout to associate logos of institutions with specific TNX drug candidates.other
Open slide detailLoop · Golden Circle
28
other
Open slide detailBeat · TeamLoop · Golden Circle
29
Standard corporate closing slide.summarize
Open slide detailLoop · Golden Circle